^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersBIOMARKER:
HER-2 amplification + HR-positive
i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
1m
Sacituzumab Tirumotecan Plus Bevacizumab for Advanced HER2-Negative Breast Cancer with Brain Metastasis (ChiCTR2500110590)
P2, N=38, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
HR positive • HER-2 negative • HR negative • HR positive + HER-2 negative • HER-2 amplification + HR-positive • HER-2 negative + HR negative
|
Avastin (bevacizumab) • Jiataile (sacituzumab tirumotecan)
1m
A single-center, randomized, non-comparative, phase II clinical trial of low-dose neratinib maleate combined with trastuzumab biosimilar and albumin paclitaxel neoadjuvant in the treatment of HER-2-positive/HR-positive early or locally advanced breast cancer (ChiCTR2500108275)
P=N/A, N=80, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
New trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER positive • HER-2 amplification • HER-2 expression • PGR positive • HER-2 amplification + HR-positive
|
carboplatin • docetaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • albumin-bound paclitaxel
4ms
Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy. (PubMed, Medicina (Kaunas))
HER2-low tumors demonstrated similar pathological responses and survival outcomes compared to HER2-zero tumors. While a HER2-low status does not appear to define a distinct biological subtype in early BC, it remains a relevant classification for emerging HER2-targeted therapies, needing further investigation in prospective studies.
Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 amplification + HR-positive
5ms
TRIO-US B-12 TALENT: Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer (clinicaltrials.gov)
P2, N=88, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HR positive • HER-2 amplification + HR-positive
|
Enhertu (fam-trastuzumab deruxtecan-nxki) • anastrozole
5ms
Sacituzumab Govitecan in HER2-Negative Breast Cancer: Redefining Treatment Paradigms. (PubMed, J Drug Target)
Clinical trials proposing its application in locally advanced HER2-BC have also been included. Furthermore, clinical trials showcasing the combination of Sacituzumab govitecan with numerous therapeutic modalities improving patient survival and quality of life in metastatic disease have also been included in the text.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HR positive • HER-2 negative • HER-2 expression • HR positive + HER-2 negative • HER-2 amplification + HR-positive • HER-2 negative + ER positive
|
Trodelvy (sacituzumab govitecan-hziy)
5ms
Response and prognosis to neoadjuvant chemotherapy in women early breast cancer of HER2-low status. (PubMed, Front Oncol)
We also analyzed DFS and OS in PCR and nonPCR patients, and there was no statistically significant difference in DFS (p=0.29) and OS (p=0.54) between HER2-0 and HER2-low cases in PCR patients, and no difference in DFS and OS between HER2-0 and HER2-low cases in nonPCR patients. In breast cancer patients receiving neoadjuvant chemotherapy, no significant differences in chemosensitivity or prognostic outcomes were observed between HER2-low and HER2-0 tumors, considering HR expression subtypes and other current clinicopathological features.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 amplification • HER-2 expression • HER-2 underexpression • HER-2 amplification + HR-positive
6ms
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (clinicaltrials.gov)
P2, N=63, Active, not recruiting, City of Hope Medical Center | Trial completion date: May 2025 --> May 2026
Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 amplification • HER-2 amplification + HR-positive • HER-2 overexpression + HR positive
|
Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel
7ms
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer (clinicaltrials.gov)
P1, N=40, Recruiting, Emory University | Trial completion date: Apr 2025 --> Apr 2027 | Trial primary completion date: Apr 2025 --> Apr 2026
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 amplification + HR-positive
|
letrozole
7ms
IKS014 in Advanced Solid Tumors That Express HER2 (clinicaltrials.gov)
P1, N=165, Recruiting, Iksuda Therapeutics Ltd. | Trial primary completion date: Sep 2025 --> Sep 2026
Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 amplification • HER-2 expression • HER-2 amplification + HR-positive
|
caxmotabart entudotin (IKS014)
7ms
HER2-Low Breast Cancer-Current Knowledge and Future Directions. (PubMed, Medicina (Kaunas))
Differences exist between this group and HER2-null breast cancer. In this review, we provide an update on HER2-low and HER2-ultralow breast cancer, including background trial data, the evolution of HER2-low expression, current clinical guidelines, quality issues, and future directions.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 amplification • HER-2 expression • HER-2 underexpression • HER-2 amplification + HR-positive
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
9ms
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. (PubMed, Cancer Cell)
This prompted us to develop atirmociclib (PF-07220060), a next-generation CDK4 selective inhibitor...Realized dose intensification led to greater CDK4 inhibition and deeper anti-tumor responses, pointing to CDK4 target coverage as a limiting factor of CDK4/6 inhibitor efficacy. We also highlight combinatorial agents that may counter acquired resistance to CDK4 selective inhibition and widen its clinical application.
Preclinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 amplification + HR-positive
|
atirmociclib (PF-07220060)
9ms
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (clinicaltrials.gov)
P2, N=63, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> May 2025
Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 amplification • HER-2 amplification + HR-positive • HER-2 overexpression + HR positive
|
Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel
Share via
